Results 191 to 200 of about 74,509 (297)

Class 3 MAPK Mutation in Langerhans cell histiocytosis and Trametinib—Reporting Two Contrarian Responses

Pediatric Blood &Cancer, Volume 72, Issue 10, October 2025.
Natalia Wojciechowska, Alejandra Cervantes‐Dominguez, Jason Wang, Anish Ray   +3 more
wiley   +1 more source

Clinicians' experience on the effectiveness of pharmacotherapy in patients with first-episode depression: a randomized controlled trial based on pharmacogenomics. [PDF]

Front Pharmacol
Tong J, Yuan J, Qin Y, Zhu N, Zhang T, Zhu X, Xu Y, Liu M, Zhang J, Sun X.   +9 more
europepmc   +1 more source

Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics [PDF]

, 2003
Araba A. Adjei, Bianca A. Thomae, Janel L Prondzinski, Bruce W. Eckloff, Eric D. Wieben, Richard M. Weinshilboum   +5 more
openalex   +1 more source

The Fortunes of Genomic Medicine: A Quarter Century of Promise

Annals of Human Genetics, Volume 89, Issue 5, Page 342-353, September 2025.
ABSTRACT Background The culmination of the Human Genome Project in the early 2000s came wreathed in promises of a revolution in medicine and healthcare. The ensuing quarter century has seen remarkable growth in genomic medicine, as well as notable shifts in the promissory rhetoric that accompanies it.
Steve Sturdy
wiley   +1 more source

Current State of Pharmacogenomic Implementation Into Care for Persons With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Tillman EM, McKinzie C, Young D, Kam C.
europepmc   +1 more source

Pharmacogenomics: road to anticancer therapeutics nirvana? [PDF]

, 2003
Apurva A. Desai, Federico Innocenti, Mark J. Ratain   +2 more
openalex   +1 more source

Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource

Alimentary Pharmacology &Therapeutics, Volume 62, Issue 6, Page 630-645, September 2025.
Carriage of any loss of function NUDT15 varaint is associated with an increased risk of thiopurine‐induced myelosuppression. Pre‐treatment genotype testing of NUDT15. ABSTRACT Background The clinical utility and cost‐effectiveness of pre‐thiopurine NUDT15 pharmacogenetic testing in European and admixed populations are unknown.
Christopher Roberts, Jaime Peters, Aleksejs Sazonvos, Neil Goodman, Mohmmed Sharip, Rebecca Smith, Maria Bishara, Claire Bewshea, Simeng Lin, Neil Chanchlani, Phoebe Hodges, Fakhirah Badrulhisham, Aamir Saifuddin, Sean Carlson, Andrea Centritto, Alexandra Marley, Muhammad Saad, Karishma Sethi‐Aora, Laura White, Alaa Abdelmeguid, Laetitia Pele, Shaji Sebastian, Christian Selinger, Peter Irving, Laura Fachal, Gareth Walker, Rachel Palmer, Nick Kennedy, Jayne Houghton, Mary Doona, Christopher Lamb, Chris Hyde, Miles Parkes, James Goodhand, Tariq Ahmad   +34 more
wiley   +1 more source

Pharmacogenomics Education and Knowledge Assessment in Healthcare Curricula: A Scoping Review of the Middle East and North Africa Region. [PDF]

Pharmacol Res Perspect
Ibrahim A, Alenany R, Bader L, Nazar F, Abulola S, Almasalmeh O, Riaz S, Zahroh H, Mraiche F.   +8 more
europepmc   +1 more source

Pharmacogenomic Analysis of Mechanisms Mediating Ethanol Regulation of Dopamine β-Hydroxylase [PDF]

, 2003
Sajida Hassan, Bao Duong, Kwang‐Soo Kim, Michael F. Miles   +3 more
openalex   +1 more source

Pharmacogenomics

Annals of Oncology, 2007
openaire   +2 more sources